Literature DB >> 36057733

Outcomes of catheter ablation versus antiarrhythmic therapy in patients with atrial fibrillation: a systematic review and meta-analysis.

Radhika Deshpande1, Yasser AlKhadra2, Prashanth Singanallur3, Albert Botchway3, Mohamed Labedi2.   

Abstract

BACKGROUND: Recent data have shown an advantage of rhythm control over rate control for the treatment of atrial fibrillation (AF). Nevertheless, the data regarding efficacy of catheter ablation (CA) compared with antiarrhythmic drugs (AADs) in patients with AF is lacking. Therefore, we sought to evaluate recurrence of arrhythmia, all-cause mortality, cardiovascular deaths, stroke/TIA, and all-cause readmissions of CA compared with AAD in patients with AF.
METHODS: Systematically searched through PubMed, Google Scholar, EMBASE, and Cochrane for randomized control trials that compared CA and AAD in atrial fibrillation patients. Review Manager 5.4 and OpenMetaAnalyst were used to analyze the data. Data was pooled for the outcomes using random-effect models (DerSimonian and Laird) and reported as pooled odds ratio (OR).
RESULTS: A total of 4822 patients were included. The CA group had 2417 patients while the AAD group included 2405 patients. Pooled data demonstrated that the CA arm had a statistically significant decrease in risk for recurrence of arrhythmia as compared to AAD (OR 0.25; [95% CI, 0.18-0.36]; p < 0.001). All-cause readmission was statistically significantly lower in CA as compared to AAD (OR 0.33; [95%CI, 0.17-0.63]; p < 0.001). For other secondary outcomes, there was no statistically significant difference between CA and AAD with regard to all-cause mortality (OR 0.75; [95% CI, 0.55-1.03]), cardiovascular death (OR 0.76; [95% CI, 0.22-2.54]), bleeding (OR 1.09, [95% CI 0.74, 1.61]), or stroke/TIA outcome (OR 0.90, [95% CI, 0.59-1.37]).
CONCLUSIONS: In this study of pooled data from 16 RCTs, CA utilization for atrial fibrillation had improved freedom from arrhythmia as well as reduced all-cause readmission compared with AAD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antiarrhythmic medication; Atrial fibrillation; Catheter ablation; Rhythm control

Year:  2022        PMID: 36057733     DOI: 10.1007/s10840-022-01365-z

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.759


  35 in total

1.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

2.  Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study.

Authors:  Carlo Pappone; Gabriele Vicedomini; Giuseppe Augello; Francesco Manguso; Massimo Saviano; Mario Baldi; Andrea Petretta; Luigi Giannelli; Zarko Calovic; Vladimir Guluta; Luigi Tavazzi; Vincenzo Santinelli
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-09-23

3.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study).

Authors:  Giuseppe Stabile; Emanuele Bertaglia; Gaetano Senatore; Antonio De Simone; Franco Zoppo; Giovanni Donnici; Pietro Turco; Pietro Pascotto; Massimo Fazzari; Dino Franco Vitale
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

4.  A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).

Authors:  Ross J Hunter; Thomas J Berriman; Ihab Diab; Ravindu Kamdar; Laura Richmond; Victoria Baker; Farai Goromonzi; Vinit Sawhney; Edward Duncan; Stephen P Page; Waqas Ullah; Beth Unsworth; Jamil Mayet; Mehul Dhinoja; Mark J Earley; Simon Sporton; Richard J Schilling
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-01-01

5.  Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Zain Ul Abideen Asad; Ali Yousif; Muhammad Shahzeb Khan; Sana M Al-Khatib; Stavros Stavrakis
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-08-21

6.  Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.

Authors:  Paulus Kirchhof; A John Camm; Andreas Goette; Axel Brandes; Lars Eckardt; Arif Elvan; Thomas Fetsch; Isabelle C van Gelder; Doreen Haase; Laurent M Haegeli; Frank Hamann; Hein Heidbüchel; Gerhard Hindricks; Josef Kautzner; Karl-Heinz Kuck; Lluis Mont; G Andre Ng; Jerzy Rekosz; Norbert Schoen; Ulrich Schotten; Anna Suling; Jens Taggeselle; Sakis Themistoclakis; Eik Vettorazzi; Panos Vardas; Karl Wegscheider; Stephan Willems; Harry J G M Crijns; Günter Breithardt
Journal:  N Engl J Med       Date:  2020-08-29       Impact factor: 91.245

7.  Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.

Authors:  Sandeep Prabhu; Andrew J Taylor; Ben T Costello; David M Kaye; Alex J A McLellan; Aleksandr Voskoboinik; Hariharan Sugumar; Siobhan M Lockwood; Michael B Stokes; Bhupesh Pathik; Chrishan J Nalliah; Geoff R Wong; Sonia M Azzopardi; Sarah J Gutman; Geoffrey Lee; Jamie Layland; Justin A Mariani; Liang-Han Ling; Jonathan M Kalman; Peter M Kistler
Journal:  J Am Coll Cardiol       Date:  2017-08-27       Impact factor: 24.094

8.  Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.

Authors:  Luigi Di Biase; Prasant Mohanty; Sanghamitra Mohanty; Pasquale Santangeli; Chintan Trivedi; Dhanunjaya Lakkireddy; Madhu Reddy; Pierre Jais; Sakis Themistoclakis; Antonio Dello Russo; Michela Casella; Gemma Pelargonio; Maria Lucia Narducci; Robert Schweikert; Petr Neuzil; Javier Sanchez; Rodney Horton; Salwa Beheiry; Richard Hongo; Steven Hao; Antonio Rossillo; Giovanni Forleo; Claudio Tondo; J David Burkhardt; Michel Haissaguerre; Andrea Natale
Journal:  Circulation       Date:  2016-03-30       Impact factor: 29.690

9.  Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study.

Authors:  Pierre Jaïs; Bruno Cauchemez; Laurent Macle; Emile Daoud; Paul Khairy; Rajesh Subbiah; Mélèze Hocini; Fabrice Extramiana; Fréderic Sacher; Pierre Bordachar; George Klein; Rukshen Weerasooriya; Jacques Clémenty; Michel Haïssaguerre
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

10.  Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.

Authors:  Douglas L Packer; Daniel B Mark; Richard A Robb; Kristi H Monahan; Tristram D Bahnson; Jeanne E Poole; Peter A Noseworthy; Yves D Rosenberg; Neal Jeffries; L Brent Mitchell; Greg C Flaker; Evgeny Pokushalov; Alexander Romanov; T Jared Bunch; Georg Noelker; Andrey Ardashev; Amiran Revishvili; David J Wilber; Riccardo Cappato; Karl-Heinz Kuck; Gerhard Hindricks; D Wyn Davies; Peter R Kowey; Gerald V Naccarelli; James A Reiffel; Jonathan P Piccini; Adam P Silverstein; Hussein R Al-Khalidi; Kerry L Lee
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.